Disc Medicine (NASDAQ:IRON) Insider Rahul Khara Sells 1,649 Shares of Stock

Disc Medicine, Inc. (NASDAQ:IRON) insider Rahul Khara sold 1,649 shares of the stock in a transaction on Monday, June 29th. The shares were sold at an average price of $75.00, for a total transaction of $123,675.00. Following the sale, the insider directly owned 52,173 shares of the company’s stock, valued at $3,912,975. The trade was a 3.06% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Rahul Khara also recently made the following trade(s):

• On Friday, June 26th, Rahul Khara sold 851 shares of Disc Medicine stock. The shares were sold at an average price of $75.00, for a total transaction of $63,825.00.
• On Thursday, June 18th, Rahul Khara sold 7,500 shares of Disc Medicine stock. The stock was sold at an average price of $70.22, for a total transaction of $526,650.00.

Disc Medicine Stock Down 1.8%

NASDAQ IRON opened at $73.14 on Wednesday. The stock has a market capitalization of $2.79 billion, a PE ratio of -11.05 and a beta of 0.93. Disc Medicine, Inc. has a 1 year low of $40.00 and a 1 year high of $99.50. The business’s 50-day moving average is $69.01 and its 200 day moving average is $70.63. The company has a debt-to-equity ratio of 0.04, a current ratio of 24.00 and a quick ratio of 24.00.

Disc Medicine (NASDAQ:IRON) last announced its earnings results on Tuesday, May 5th. The company reported ($1.65) EPS for the quarter, missing analysts’ consensus estimates of ($1.62) by ($0.03). Sell-side analysts forecast that Disc Medicine, Inc. will post -6.74 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of IRON. JPMorgan Chase & Co. grew its holdings in Disc Medicine by 110.0% in the fourth quarter. JPMorgan Chase & Co. now owns 1,581,127 shares of the company’s stock worth $125,557,000 after purchasing an additional 828,248 shares during the period. BVF Inc. IL bought a new stake in shares of Disc Medicine in the 4th quarter worth approximately $51,616,000. Jennison Associates LLC purchased a new stake in shares of Disc Medicine in the 4th quarter worth approximately $42,252,000. Perceptive Advisors LLC purchased a new stake in shares of Disc Medicine in the 4th quarter worth approximately $35,794,000. Finally, RA Capital Management L.P. increased its position in Disc Medicine by 25.3% during the 4th quarter. RA Capital Management L.P. now owns 1,976,132 shares of the company’s stock valued at $156,925,000 after buying an additional 399,026 shares in the last quarter. 83.70% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the stock. Wedbush reaffirmed an “outperform” rating and set a $88.00 target price on shares of Disc Medicine in a research note on Wednesday, June 10th. Weiss Ratings reissued a “sell (d-)” rating on shares of Disc Medicine in a research note on Monday, April 20th. Wall Street Zen upgraded shares of Disc Medicine from a “strong sell” rating to a “sell” rating in a report on Saturday, April 25th. Finally, Morgan Stanley lifted their price objective on Disc Medicine from $80.00 to $85.00 and gave the company an “overweight” rating in a research report on Monday, June 15th. Ten analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Disc Medicine presently has an average rating of “Moderate Buy” and a consensus target price of $105.80.

About Disc Medicine

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.